The Enterprise Value as of September 2024 (TTM) for Cell Source, Inc. (CLCS) is 25.85M

According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 25.85M. This represents a change of 13.07% compared to the average of 22.87M of the last 4 quarters.

Cell Source, Inc. (CLCS) Historical Enterprise Value (quarterly & annually)

How has CLCS Enterprise Value performed in the past?

The mean historical Enterprise Value of Cell Source, Inc. over the last ten years is 30.25M. The current 25.85M Enterprise Value has changed 8.45% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Enterprise Value was at its highest in in the June 2021 quarter at 70.49M. The Enterprise Value was at its lowest in in the September 2022 quarter at 7.20M.

Cell Source, Inc. (CLCS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cell Source, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cell Source, Inc. (CLCS) Average Enterprise Value

How has CLCS Enterprise Value performed in the past?

The current Enterprise Value of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cell Source, Inc. (CLCS) Enterprise Value vs. Peers

How is CLCS’s Enterprise Value compared to its peers?

Cell Source, Inc.’s Enterprise Value is less than Emmaus Life Sciences, Inc. (31.39M), greater than Adhera Therapeutics, Inc. (10.80M), greater than PolarityTE, Inc. (-1663329.00), less than ZIVO Bioscience, Inc. (47.70M), greater than Pasithea Therapeutics Corp. (-2955980.00), less than Nutriband Inc. (55.59M), less than MediciNova, Inc. (39.04M), less than Eliem Therapeutics, Inc. (332.22M), greater than Panbela Therapeutics, Inc. (5.93M), greater than Virpax Pharmaceuticals, Inc. (1.75M), greater than Revelation Biosciences, Inc. (-8466731.00), greater than Biodexa Pharmaceuticals Plc (-5433125.02), less than Praxis Precision Medicines, Inc. (975.86M), greater than Cardio Diagnostics Holdings, Inc. (6.26M), less than Sigilon Therapeutics, Inc. (43.98M), greater than Sonnet BioTherapeutics Holdings, Inc. (2.01M), greater than ZyVersa Therapeutics, Inc. (2.32M), less than X4 Pharmaceuticals, Inc. (50.24M), greater than eFFECTOR Therapeutics, Inc. (3.85M), less than Landos Biopharma, Inc. (42.62M), greater than Apexigen, Inc. (205.32K), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Angion Biomedica Corp. (22.43M),

Build a custom stock screener for Cell Source, Inc. (CLCS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cell Source, Inc. (CLCS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.